Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.150
-0.020 (-1.71%)
At close: Apr 28, 2026, 4:00 PM EDT
1.170
+0.020 (1.74%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Inovio Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Inovio Pharmaceuticals stock have an average target of 6.75, with a low estimate of 3.00 and a high estimate of 13. The average target predicts an increase of 486.96% from the current stock price of 1.15.
Analyst Consensus: Buy
* Price targets were last updated on Nov 14, 2025.
Analyst Ratings
The average analyst rating for Inovio Pharmaceuticals stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $5 → $6 | Buy | Reiterates | $5 → $6 | +421.74% | Nov 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $3 | Hold | Reiterates | $3 | +160.87% | Aug 14, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $5 | Buy | Initiates | $5 | +334.78% | Jul 9, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $5 | Hold | Reiterates | $5 | +334.78% | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $15 → $13 | Buy | Maintains | $15 → $13 | +1,030.43% | May 14, 2025 |
Financial Forecast
Revenue This Year
13.24M
from 65.34K
Increased by 20,156.19%
Revenue Next Year
69.09M
from 13.24M
Increased by 421.95%
EPS This Year
-1.22
from -1.81
EPS Next Year
-0.54
from -1.22
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 43.6M | 128.5M | ||||||
| Avg | 13.2M | 69.1M | ||||||
| Low | n/a | 33.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 66,618.7% | 870.8% | ||||||
| Avg | 20,156.2% | 421.9% | ||||||
| Low | - | 151.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.90 | -0.01 | ||||||
| Avg | -1.22 | -0.54 | ||||||
| Low | -1.53 | -1.20 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.